Submissions for paper, poster and workshop presentations must be submitted online by June 1, 2012. Online submission forms, instructions and examples are available at www.aaap.org. Submission Categories • Paper Presentations offer an opportunity to briefly present research findings or data on clinical experiences. These presentations are organized into concurrent 60-minute sessions with each abstract presentation 10 minutes in duration followed by an additional 5 minute question/answer period. • Posters are displayed throughout the conference with the author(s) hosting informal discussions about their work. • Workshops are 90-minute sessions which emphasize an interactive learning process around a specific topic. The emphasis will be on skills development and small group discussion as opposed to dissemination of information in a lecture format. 400 Massasoit Avenue Suite 307 - 2nd Floor East Providence, RI 02914 Phone: (401) 524-3076 Fax: (401) 272-0922 www.aaap.org American Academy of Addiction Psychiatry American Academy of Addiction Psychiatry Inc. 1985 The following guidelines apply to submission of proposals for all presentations Paper and Poster Presentations Submissions must contain data (either quantitative or qualitative) and report research results. Submissions should be organized under the following headings: Background: Describe the importance of the study and state the objective(s). Methods: Provide a description of the methods used: study design, setting, population, measures, and analytic procedures. Results: Describe the results to support the conclusions. Conclusions: State the implications of the findings for clinical practice, research, education, and/or policy. Funding: Indicate source of funding (i.e., NIH Institute, Foundation, Health Care Company, Pharmaceutical, etc). Authors should indicate their presentation preference (poster or paper) on the abstract submission form. The same paper may not be submitted for both a paper presentation and poster. During the review process, the Review Committee may recommend the author convert a paper submission to a poster. Papers that have been published or accepted for publication either in article or abstract form prior to the abstract submission deadline will not be eligible for review. Papers under review at the time of the submission deadline but not yet accepted for publication, even if appearing before the meeting, are eligible for presentation. Call for Abstracts 23 rd Annual Meeting and Symposium Turnberry Isle Hotel Miami, Aventura, Florida December 6-9, 2012
Transcript
Submissions for paper, poster and workshop presentations must be submitted online by June 1, 2012.
Online submission forms, instructions and examples are available at www.aaap.org.
Submission Categories
• Paper Presentations offer an opportunity to briefl y present research fi ndings or data on clinical experiences. These presentations are organized into concurrent 60-minute sessions with each abstract presentation 10 minutes in duration followed by an additional 5 minute question/answer period.
• Posters are displayed throughout the conference with the author(s) hosting informal discussions about their work.
• Workshops are 90-minute sessions which emphasize an interactive learning process around a specifi c topic. The emphasis will be on skills development and small group discussion as opposed to dissemination of information in a lecture format.
The American Academy of Addiction Psychiatry encourages abstract submissionsfor paper, poster and workshop presentations by and about racial and ethnic
minorities and women, as well as other underrepresented groups.
400 Massasoit AvenueSuite 307 - 2nd Floor
East Providence, RI 02914Phone: (401) 524-3076
Fax: (401) 272-0922www.aaap.org
American Academy of Addiction PsychiatryAm
eric
an
Aca
dem
y of
Addiction Psych
iatry
Inc.
1985
The following guidelines apply to submission of proposals for all presentations
Paper and Poster Presentations
Submissions must contain data (either quantitative or qualitative) and report research results.
Submissions should be organized under the following headings:
Background: Describe the importance of the study and state the objective(s).
Methods: Provide a description of the methods used: study design, setting, population, measures, and analytic procedures.
Results: Describe the results to support the conclusions.
Conclusions: State the implications of the fi ndings for clinical practice, research, education, and/or policy.
Funding: Indicate source of funding (i.e., NIH Institute, Foundation, Health Care Company, Pharmaceutical, etc).
Authors should indicate their presentation preference (poster or paper) on the abstract submission form. The same paper may not be submitted for both a paper presentation and poster. During the review process, the Review Committee may recommend the author convert a paper submission to a poster.
Papers that have been published or accepted for publication either in article or abstract form prior to the abstract submission deadline will not be eligible for review. Papers under review at the time of the submission deadline but not yet accepted for publication, even if appearing before the meeting, are eligible for presentation.
Call for Abstracts
23rd Annual Meeting and SymposiumTurnberry Isle Hotel Miami, Aventura, Florida
December 6-9, 2012
For further information email [email protected] or call (401) 524-3076.
Disclaimer: AAAP is a private, non-profi t organization which reserves the right to remove any presentation from its’ public forums if questions arise that may compro-mise the reputation of AAAP. Presentations may be withdrawn by AAAP for various reasons which include, but are not limited to: 1) concerns about pharmaceuticalor private corporate infl uence on or funding for work to be presented, 2) questions regarding the research methodology, analysis and conclusions, or 3) evidencethat data was altered or misrepresented.
Worksho
p
Worksho
p
Sample
Sample
Paper a
nd Post
er
Paper a
nd Post
er
Sample
Sample
Title: Naltrexone Treatment Alcohol Dependence in Schizophrenia: Effects on Depression and Psychosis SeveritySteven L. Batki, MD1, 2; Jacqueline A. Dimmock, PhD2; Robert Ploutz-Snyder, PhD3; Michelle Cavallerano, BA2; Luba Leontieva, PhD2; Sara DeRycke, BA2; Zsuzsa Szombathyne Meszaros, PhD2; Kelly Canfi eld, RN, NP2. 1 Department of Psychiatry, University of California, San Francisco and SF VA Medical Center; 2Department of Psychiatry, SUNY Upstate Medical University; 3Department of Medicine, SUNY Upstate Medical University
Background/Objective: A preliminary analysis of the effects of naltrexone (NTX) treatment on depression and psychosis severity in patients with schizophrenia and alcohol dependence. While NTX has shown promise in the treatment of alcohol dependence in serious mental illness, questions exist regarding its effects on mood and psychosis.
Methods: 90 subjects with schizophrenia/schizoaffective disorder and alcohol abuse/dependence were assigned to 12 weeks of naltrexone or placebo treatment. Mean baseline PANSS scores were: Positive 15.4, Negative 13.5, Composite 1.9, General 32.3. Mean baseline Calgary Depression score was 5.2. Multi-level modeling analysis was conducted of longitudinal treatment effects on PANSS and Calgary scores from baseline to study end, by treatment group and adherence. “Adherent” partici-pants received at least 80% of study medication; “non-adherent” less than 80%.
Results: Preliminary multi-level modeling of longitudinal treatment effects on PANNS Positive, Negative, Composite, and General scores from baseline by group revealed no signifi cant main effects or interactions involving treatment group; thus, no signifi cant changes in PANNS scores were observed for either group. Treatment main effects and interactions in our multi-level model of Calgary scores were also non-signifi cant, however we did observe a decrease in Calgary scores over time in the Placebo group (p<.05), a decrease that occurred only in “non-adherent” subjects.
Conclusions: Patients with schizophrenia and alcohol use disorders treated with naltrexone did not demonstrate increased depression; nor did they demonstrate im-provement of psychotic symptoms. Further analyses may be necessary to explore possible relationships between changes in alcohol use and psychiatric symptoms in schizophrenia.
Source of Funding: NIAAA RO1 AA013655
Workshops
Workshops should be interactive, with an emphasis on audience participation in discussions, skill-building exercises, etc. Participation in workshops should impact attendee’s teaching, clinical, policy and/or administrative work.
Learning Objective(s): Provide the objective of the workshop. Learning objectives are a tool to assist in identifying the specifi c steps that will be taken to address the gap between an identifi ed need and the “best practice”. This is what the participant should be able to do as a result of the CME activity.
Brief Summary of Workshop: Describe the workshop in 250 words or less.
Contents and Methods: Describe the identifi ed objectives to be accomplished. List the methods, strategies, materials and resources to be used in the workshop. Please specify the techniques that you will use for skill-building and facilitating discussion in meeting the
goal of making this an interactive session. Note: No more than half of the workshop time (45 minutes or less) will be spent on presentation with the remaining time dedicated to discussion and interactive exercises with the participants.
Additional Presenters: List name, degree, and institutional affi liation for any additional presenters who will be involved in the workshop
Funding: Indicate source of funding, (i.e., NIH Institute, Foundation, Health Care Company, Pharmaceutical, etc.)
Implementing Contingency Management Techniques in a Community Treatment Program
Workshop Presenters: David Lott, MD, Linden Oaks Hospital and University of Illinois at Chicago; Alan Budney, PhD, University of Arkansas for Medical Sciences; andJessica Novak, MSW, LCSW, Linden Oaks Hospital.
At the end of the workshop participants will be able to: 1. Describe the rationale for use of contingency management (CM) methods 2. Identify the methods and materials needed to start a CM program 3. Anticipate the challenges faced when developing and implementing a successful CM program
Contingency management (CM) is a powerful treatment approach with consistent empirical support and large effects, but which is underutilized in community treatment. This workshop will provide information and interactive experience to explore the barriers to CM use and encourage implementation of practical, low-cost techniques. The faculty will fi rst review relevant behavioral theory to provide the background and history of CM development. Next they will present research fi ndings in the use of several important types of CM methods used successfully in treating Addiction. Participants will then watch a live demonstration of the CM process in use at Linden Oaks Hospital, including an interactive experience with this technique. Participants and faculty will discuss this specifi c CM program, based on the Fishbowl Method, including the process of implementing and sustain-ing the program, as well as outcome results at this treatment site. This workshop will provide an important training opportunity by helping participants fi nd ways to take advantage of a powerful but underutilized treatment approach.
Dr. Budney will present background information including an overview of the behavioral principles that guide CM approaches, a synopsis of the large body of CM research dem-onstrating its effectiveness, and highlights of his experience using CM methods in research settings. Dr. Lott will describe the process of choosing a CM approach and starting it in the adolescent treatment program at Linden Oaks Hospital. He and Dr. Novak will conduct a participatory demonstration the program currently in use. They will then present data showing the impact of this CM program on fi nancial, staff, and patient outcomes.
The workshop will conclude with an interactive discussion of CM and its’ generalizability to other treatment settings and patient populations. This will include a review of barriers often faced in using CM in a community setting such as cost, philosophical objections, and maintaining the program, and suggestions for overcoming these barriers.
